8-K: Acadia Healthcare Reports Q4 Loss, Lower 2026 Outlook

Acadia Healthcare announced a significant net loss for Q4 and full-year 2025 due to a goodwill impairment and legal settlements, alongside a reduced financial outlook for 2026.

Summary

• Acadia Healthcare reported fourth quarter 2025 revenue of $821.5 million, a 6.1% increase year-over-year, exceeding the high end of its implied guidance.
• Same facility revenue increased by 4.4% in Q4 2025, driven by a 3.1% increase in patient days and a 1.3% increase in revenue per patient day.
• The company recorded a net loss attributable to Acadia of $(13.02) per diluted share for Q4 2025, primarily due to a non-cash goodwill impairment charge of $996.2 million and $147 million in legal settlements expense.
• Adjusted net income attributable to Acadia for Q4 2025 was $6.1 million, or $0.07 per diluted share, a decrease from $59.2 million, or $0.64 per diluted share, in the prior-year period.
• Adjusted EBITDA for Q4 2025 was $99.8 million, at the upper end of implied guidance, but down from $153.1 million in Q4 2024, reflecting a $52.7 million adjustment to professional and general liability (PLGL) reserves.
• For the full year 2025, revenue totaled $3,312.8 million (up 5.0%), with a net loss of $(12.16) per diluted share and adjusted EBITDA of $608.9 million.
• Acadia added 1,089 licensed beds in 2025, including 311 to existing facilities and 778 from new facilities.
• Full year 2026 financial guidance projects revenue of $3.37 to $3.45 billion, adjusted EBITDA of $575 to $610 million, and adjusted earnings per diluted share of $1.30 to $1.55.
• The 2026 guidance includes anticipated headwinds from a New York Medicaid policy change ($25-$30 million negative impact on adjusted EBITDA) and a decrease in existing Medicaid supplemental payments ($15-$20 million).

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to the substantial net loss driven by goodwill impairment and legal settlements, coupled with a downward revision in 2026 financial guidance for key adjusted metrics.

Positives

• Fourth quarter 2025 revenue of $821.5 million increased 6.1% year-over-year and exceeded the high end of the company's implied guidance.
• Same facility revenue increased 4.4% in Q4 2025, driven by a 3.1% increase in patient days and a 1.3% increase in revenue per patient day.
• Adjusted EBITDA for Q4 2025 was $99.8 million, reaching the upper end of the company's implied fourth-quarter guidance range.
• Acadia added a significant 1,089 licensed beds during 2025, including 778 from new facilities and 311 to existing facilities, indicating continued expansion.
• The company commenced operations at the 144-bed ECU Health Behavioral Health Hospital, a joint venture facility, expanding its service offerings.

Negatives

• Acadia reported a substantial net loss attributable to Acadia of $(13.02) per diluted share for Q4 2025, compared to net income of $0.35 per diluted share in the prior-year period.
• The Q4 2025 net loss was primarily driven by a non-cash goodwill impairment charge of $996.2 million.
• Adjusted net income attributable to Acadia significantly decreased to $6.1 million ($0.07 per diluted share) in Q4 2025 from $59.2 million ($0.64 per diluted share) in Q4 2024.
• Adjusted EBITDA declined to $99.8 million in Q4 2025 from $153.1 million in Q4 2024, partly due to a $52.7 million adjustment to professional and general liability (PLGL) reserves.
• Full year 2025 net loss attributable to Acadia was $(12.16) per diluted share, a significant reversal from net income of $2.78 per diluted share in 2024.
• Full year 2025 adjusted EBITDA decreased to $608.9 million from $709.0 million in 2024.
• Full year 2026 guidance for adjusted EBITDA ($575-$610 million) and adjusted earnings per diluted share ($1.30-$1.55) is lower than 2025 actuals ($608.9 million and $2.00, respectively).
• The company anticipates a $25 to $30 million negative impact on adjusted EBITDA in 2026 due to changes in New York Medicaid policy regarding out-of-state facilities.
• A decrease of $15 to $20 million in existing Medicaid supplemental payments, net of provider taxes, is expected in 2026.

Risks

• Potential difficulties in successfully integrating operations of acquired facilities or realizing expected benefits and synergies from facility expansions, acquisitions, joint ventures, and de novo transactions.
• Challenges in the company's ability to add beds, expand services, enhance marketing programs, and improve efficiencies at its facilities.
• Potential reductions in payments received from government and commercial payors, including significant changes to Medicaid financing mechanisms introduced by the One Big Beautiful Bill Act (OBBBA) enacted on July 4, 2025.
• The occurrence of patient incidents, governmental investigations, litigation, and adverse regulatory actions, which could adversely affect the stock price and result in substantial payments and incremental regulatory burdens.
• Changes in expectations resulting from actuarial and other reviews of the company's liability reserves and other aspects of its business.
• The risk that the company may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements.
• Potential disruptions to the company's information technology systems or a cybersecurity incident.
• Potential operating difficulties, including disruption to the U.S. economy and financial markets, reduced admissions and patient volumes (partly due to OBBBA's work or community engagement requirements in the Medicaid expansion population), increased costs relating to labor, supply chain, and other expenditures, changes in competition and client preferences, and general economic or industry conditions.

Future Outlook

Acadia Healthcare has provided full-year 2026 financial guidance, projecting revenue between $3.37 and $3.45 billion, adjusted EBITDA of $575 to $610 million, and adjusted earnings per diluted share of $1.30 to $1.55. This guidance anticipates same-facility volume growth of 0% to 1% and revenue per patient day growth of 2% to 3%. Key assumptions include startup losses of $47 to $53 million, a negative impact of $25 to $30 million on adjusted EBITDA from New York Medicaid policy changes, and a $15 to $20 million decrease in existing Medicaid supplemental payments. The company also expects to add 400 to 600 beds in 2026.

Management Comments

• "Our results for the fourth quarter reflect improved volume growth with year-over-year revenue growth of 6%."
• "While we work to address the ongoing challenges affecting our business, my key priorities as CEO are to bring steady leadership, reinforce operational discipline, and help position the Company for long-term success."
• "I have great confidence in our teams and in the long-term strategic direction of the Company, and I am fully committed to supporting Acadia through this next phase of execution and operational improvement."

Industry Context

StockSavvy.ai notes that the behavioral healthcare sector continues to face evolving regulatory landscapes, as evidenced by the impact of the One Big Beautiful Bill Act (OBBBA) and changes in state-level Medicaid policies. While demand for behavioral health services remains strong, providers like Acadia must navigate complex reimbursement structures and rising operating costs, particularly related to labor and professional liability. The industry is also seeing continued expansion through new facility development and bed additions to meet growing patient needs, but this growth comes with initial startup losses and integration challenges.

Comparison to Industry Standards

• The significant non-cash goodwill impairment charge of $996.2 million suggests a re-evaluation of asset values, which can be a concern for investors, especially when compared to peers who may not be reporting similar large-scale impairments.
• The decrease in Adjusted EBITDA and Adjusted EPS for both Q4 and full-year 2025, along with lower 2026 guidance compared to 2025 actuals, indicates a performance slowdown relative to prior periods, which could lag behind more robust growth seen in some segments of the healthcare industry.
• The 4.0x net leverage ratio as of December 31, 2025, while within typical ranges for healthcare providers, is on the higher side, potentially limiting financial flexibility compared to less leveraged competitors.

Management Changes

Legal Proceedings

• Legal settlements expense of $147 million was incurred, primarily for the settlement of the 2019 securities litigation (St. Clair County Employees Retirement System v. Acadia Healthcare Company, Inc., et al., Case No. 3:19-cv-00988) and costs associated with the Desert Hills litigation.
• Government investigations resulted in costs of $11.985 million for Q4 2025 and $135.259 million for the full year 2025.

Stakeholder Impact

• Shareholders: Significant net loss and lower 2026 guidance could negatively impact share price and investor confidence.
• Employees: Routine annual wage increases were noted, but workforce reductions and restructuring costs are mentioned as components of transaction, legal and other costs in the footnotes, indicating potential impact.
• Customers/Patients: Continued expansion through new beds and facilities aims to serve more patients, but changes in Medicaid policy could affect access or service provision for some populations.
• Creditors: Increased borrowings led to higher interest expense, and a net leverage ratio of 4.0x adjusted EBITDA indicates a notable debt burden, which creditors will monitor.

Next Steps

• Acadia will conduct a conference call on February 25, 2026, at 9:00 a.m. Eastern Time to discuss its fourth quarter and year-end 2025 financial results.
• The company plans to add 400 to 600 licensed beds in 2026, continuing its facility expansion strategy.
• Acadia is monitoring potential new or expanded supplemental programs which could represent at least a $22 million annual run rate benefit to adjusted EBITDA if approved by CMS.

Key Dates

Recommendation

The filing reveals a substantial net loss driven by a large goodwill impairment and significant legal settlement costs, indicating underlying operational and historical issues. While Q4 revenue and adjusted EBITDA met implied guidance, the full-year adjusted metrics are down, and the 2026 guidance for adjusted EBITDA and EPS is notably lower than 2025 actuals. This downward trend, coupled with regulatory headwinds from Medicaid policy changes and increased liability reserves, suggests a challenging period ahead. The high net leverage ratio further adds to concerns. A seasoned investor would likely view these results and outlook as a strong signal to sell or reduce exposure, anticipating continued pressure on profitability and potential further downside.

Keywords

Behavioral Healthcare, Mental Health, Addiction Treatment, SEC Filing, Financial Results, Earnings Report, Healthcare Services, Goodwill Impairment, Medicaid Policy, Adjusted EBITDA, Patient Days, Facility Expansion, Corporate Governance